LAUSR

The most widespread type of liver cancer, hepatocellular carcinoma (HCC), is associated with disabled cellular death pathways. Despite therapeutic advancements, resistance to current systemic treatments (including sorafenib) compromises the prognosis of HCC patients, driving the search for agents that might target novel cell death pathways. Ferroptosis, a form of iron-mediated non-apoptotic cell death, has gained considerable attention as a potential target for cancer therapy, especially in HCC. The role of ferroptosis in HCC is complex and diverse. On one hand, ferroptosis can both contribute to the progression of HCC through its involvement in acute and chronic liver conditions. On the other hand, having ferroptosis affect HCC cells might be desirable. This review examines the role of ferroptosis in HCC from cellular, animal, and human perspectives, while examining its mechanisms, regulation, biomarkers, and clinical implications.